Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma

Published:2014-02-24 Issue:9 Volume:55 Page:2071-2078
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Nobili Stefania,Napoli Cristina,Puccini Benedetta,Landini Ida,Perrone Gabriele,Brugia Marco,Benelli Gemma,Doria Morena,Martelli Maurizio,Finolezzi Erica,Di Rocco Alice,Del Fava Emanuele,Rigacci Luigi,Di Lollo Simonetta,Bosi Alberto,Mini Enrico

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.866665

Reference48 articles.

1. Cancer statistics, 2013

2. Non-Hodgkin lymphoma

3. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

4. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

5. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma;Cancers;2023-05-13

3. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge;Pharmacology & Therapeutics;2022-01

4. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance;PLOS ONE;2017-09-15

5. Diffuse large B-cell lymphoma: R-CHOP failure—what to do?;Hematology;2016-12-02